Related Experiment Video
Updated: Jun 10, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
What is the best second-line treatment for immune thrombocytopenia?
Matthieu Mahévas1, James B Bussel2
1Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, CHU Henri Mondor, INSERM U1151/CNRS UMS 8253, Institut Necker Enfants Malades, ATIP-Avenir Team AI2B, Créteil, France.
Abstract:
The choice between thrombopoietin receptor agonists (TPO-RAs) and anti-CD20 as the preferred second-line therapies for immune thrombocytopenia remains in the eye of the beholders. Each has major advantages and certain weaknesses. Stolz et al. describe a single-centre experience that whets our appetite for a large randomized controlled trial comparing a TPO agonist and an anti-CD20 agent. Commentary on: Stolz et al. Efficacy of thrombopoietin receptor agonists versus rituximab in non-responsive immune thrombocytopenia - A single center retrospective analysis. Br J Haematol 2024; 205:1121-1125.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Tumor Immunotherapy
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

